The Globe and Mail reports in its Saturday edition that Desjardins analyst John Chu continues to rate Aurora Cannabis "buy." The Globe's David Leeder writes that Mr. Chu cut his share target to $14 from $16.50. Analysts on average target the shares at $12.24. Mr. Chu says Aurora Cannabis is facing near-term headwinds. He points to both seasonally weaker industry sales and the rising costs associated with a ramp-up toward the mid-December legalization of edibles. As a result Mr. Chu pushed back his expectation of positive earnings before interest, taxes, depreciation and amortization to early next year following last week's release of lower-than-anticipated fourth quarter results. Mr. Chu says in a note: "We also believe that the potential for additional funding to grow the existing businesses and expand into the U.S. could be a near-term overhang on the stock. However, Aurora Sky and some of its other facilities are near full ramp-up, which should open up more sales opportunities both internationally, where demand outstrips supply, and domestically, as the retail structure across Canada ramps up (Ontario and Alberta have been adding new stores lately, which should boost industry sales near year-end and in CY20)."